Focused On-demand Library for NMDA receptor synaptonuclear signaling and neuronal migration factor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6X4W1

UPID:

NSMF_HUMAN

Alternative names:

Nasal embryonic luteinizing hormone-releasing hormone factor

Alternative UPACC:

Q6X4W1; Q2TB96; Q6X4V7; Q6X4V8; Q6X4V9; Q8N2M2; Q96SY1; Q9NPM4; Q9NPP3; Q9NPS3

Background:

The NMDA receptor synaptonuclear signaling and neuronal migration factor, also known as Nasal embryonic luteinizing hormone-releasing hormone factor, plays a pivotal role in neural development. It is essential for the signaling of NMDA-sensitive glutamate receptors to the nucleus, influencing the long-lasting changes in dendrites and spine synapse processes. This protein is crucial for the outgrowth of olfactory axons and the migration of gonadotropin-releasing hormone (GnRH) and luteinizing-hormone-releasing hormone (LHRH) neuronal cells.

Therapeutic significance:

Given its involvement in Hypogonadotropic hypogonadism 9 with or without anosmia, a disorder linked to absent or incomplete sexual maturation and low levels of circulating gonadotropins and testosterone, understanding the role of this protein could lead to novel therapeutic strategies for treating this condition and potentially related reproductive and sensory disorders.